مکتبة رقمیه للعلوم الطبيه
Your cart is empty.
  • Cart
  • Lists
    Your lists Log in to create your own lists
  • Log in to your account
  • Your cookies
  • Search history
  • Advanced search
  • Authority search
  • Tag cloud
  • Library

Log in to your account

  1. Home
  2. Details for: Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.
Normal view MARC view ISBD view

Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. [electronic resource]

By:
  • Menendez, Javier A
Contributor(s):
  • Vellon, Luciano
  • Mehmi, Inderjit
  • Oza, Bharvi P
  • Ropero, Santiago
  • Colomer, Ramon
  • Lupu, Ruth
Producer: 20040826Description: 10715-20 p. digitalISSN:
  • 0027-8424
Subject(s):
  • 4-Butyrolactone -- analogs & derivatives
  • Antibodies, Monoclonal -- metabolism
  • Antibodies, Monoclonal, Humanized
  • Antifungal Agents -- metabolism
  • Antineoplastic Agents -- metabolism
  • Apoptosis
  • Biomarkers, Tumor
  • Breast Neoplasms -- genetics
  • Cell Line
  • Cell Size
  • Cell Survival
  • Cerulenin -- metabolism
  • Fatty Acid Synthases -- antagonists & inhibitors
  • Female
  • Gene Expression Regulation, Neoplastic
  • Genes, erbB-2
  • Humans
  • Ovarian Neoplasms -- genetics
  • RNA, Small Interfering -- genetics
  • Receptor, ErbB-2 -- genetics
  • Signal Transduction
  • Transcription Factors -- genetics
  • Trastuzumab
Online resources:
  • Available from publisher's website
In: Proceedings of the National Academy of Sciences of the United States of America vol. 101
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Cancel rating. Average rating: 0.0 (0 votes)
  • Holdings ( 0 )
  • Title notes ( 1 )
  • Comments ( 0 )
No physical items for this record

Publication Type: Journal Article

There are no comments on this title.

Log in to your account to post a comment.
Browse results Close
Previous
Back to results
Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 1 Hyperlipidaemia and cardiovascular disease: HDL, inflammation and surprising results of AIM-HIGH study.
    by Nofer, Jerzy-Roch
  • 2 High-density lipoprotein, sphingosine 1-phosphate, and atherosclerosis.
    by Nofer, Jerzy-Roch
  • 3 Signal transduction by HDL: agonists, receptors, and signaling cascades.
    by Nofer, Jerzy-Roch
  • 4 Estrogens and atherosclerosis: insights from animal models and cell systems.
    by Nofer, Jerzy-Roch
  • 5 Hyperlipidaemia and cardiovascular disease: the quantity does not turn into quality!
    by Nofer, Jerzy-Roch
  • 6 Hyperlipidemia and cardiovascular disease: triglycerides - a revival of cardiovascular risk factor?
    by Nofer, Jerzy-Roch
  • 7 Hyperlipidemia and cardiovascular disease: should we abandon HDL cholesterol as a therapeutic target in coronary heart disease.
    by Nofer, Jerzy-Roch
  • 8 Atheroprotective effects of high-density lipoproteins.
    by Assmann, Gerd
  • 9 Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids.
    by Nofer, Jerzy-Roch
  • 10 Frail HDLs and stiff arteries in type 2 diabetes in juveniles.
    by von Eckardstein, Arnold
  • 11 HDL scavenger receptor class B type I and platelet function.
    by Nofer, Jerzy-Roch
  • 12 Author's reply.
    by Stypmann, Jörg
  • 13 Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence.
    by Nofer, Jerzy-Roch
  • 14 Cardiovascular risk assessment in metabolic syndrome: view from PROCAM.
    by Assmann, Gerd
  • 15 Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P).
    by Potì, Francesco
  • 16 Low density receptor-related protein 1 (LRP1) promotes anti-inflammatory phenotype in murine macrophages.
    by May, Petra
  • 17 High-density lipoproteins, platelets and the pathogenesis of atherosclerosis.
    by Nofer, Jerzy-Roch
  • 18 Establishing reference intervals for sex hormones on the analytical platforms Advia Centaur and Immulite 2000XP.
    by Schüring, Andreas N
  • 19 Hypothalamic dopaminergic stimulation in cluster headache.
    by Lepper, Anne
  • 20 Low density lipoproteins inhibit the Na+/H+ antiport in human platelets via activation of p38MAP kinase.
    by Nofer, Jerzy-Roch
Close

Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.

APA

Menendez J. A., Vellon L., Mehmi I., Oza B. P., Ropero S., Colomer R. & Lupu R. (20040826). Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. : Proceedings of the National Academy of Sciences of the United States of America.

Chicago

Menendez Javier A, Vellon Luciano, Mehmi Inderjit, Oza Bharvi P, Ropero Santiago, Colomer Ramon and Lupu Ruth. 20040826. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. : Proceedings of the National Academy of Sciences of the United States of America.

Harvard

Menendez J. A., Vellon L., Mehmi I., Oza B. P., Ropero S., Colomer R. and Lupu R. (20040826). Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. : Proceedings of the National Academy of Sciences of the United States of America.

MLA

Menendez Javier A, Vellon Luciano, Mehmi Inderjit, Oza Bharvi P, Ropero Santiago, Colomer Ramon and Lupu Ruth. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. : Proceedings of the National Academy of Sciences of the United States of America. 20040826.

  • Print
  • Cite
  • Add to your cart (remove)
  • Save record
    BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
  • More searches
    Search for this title in:
    Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)

Exporting to Dublin Core...

Visit web site